EMBL Ventures GmbH

EMBL Ventures GmbH

EMBL Ventures GmbH

Overview
Date Founded

2001

Headquarters

Boxbergring 107,Heidelberg, Baden Wuerttemberg 69126

Type of Company

Private

Industries

Private Equity & Venture Capital
Accounting & Financial Services
Investment Services & Portfolio Management

Company Description

EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties.The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position.EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.

Contact Data
Trying to get in touch with decision makers at EMBL Ventures GmbH? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founding Partner

Venture Partner

Venture Partner

Managing Director

Managing Director

Paths to EMBL Ventures GmbH
Potential Connections via
Relationship Science
You
EMBL Ventures GmbH
Recent Transactions
Details Hidden

Boehringer Ingelheim Venture purchases ViraTherapeutics GmbH from EMBL Ventures GmbH, Austria Wirtschaftsservice GmbH

Details Hidden

Bruker Corp. purchases Luxendo GmbH from LSP Management Group BV, EMBL Ventures GmbH

Investments
Details Hidden

Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.

Details Hidden

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm’s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Details Hidden

Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by EMBL Ventures GmbH. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of EMBL Ventures GmbH's profile does not indicate a business or promotional relationship of any kind between RelSci and EMBL Ventures GmbH.